Titlebook: Cutaneous Biometrics; Howard Maibach,Nily Osman Book 2024Latest edition Springer Nature Switzerland AG 2024 clinical relevance percutaneou

揭发

书目名称Cutaneous Biometrics影响因子(影响力)




书目名称Cutaneous Biometrics影响因子(影响力)学科排名




书目名称Cutaneous Biometrics网络公开度




书目名称Cutaneous Biometrics网络公开度学科排名




书目名称Cutaneous Biometrics被引频次




书目名称Cutaneous Biometrics被引频次学科排名




书目名称Cutaneous Biometrics年度引用




书目名称Cutaneous Biometrics年度引用学科排名




书目名称Cutaneous Biometrics读者反馈




书目名称Cutaneous Biometrics读者反馈学科排名

讽刺

nce of creating meaningful dermatological patient outcome me.This handbook covers the essential subject areas of cutaneous biometrics, including acne, aging, genetics, eczema, psoriasis, atopic dermatitis, rosacea, wound healing, and more. Erythema of rosacea and the risk of skin ulceration associat

神化怪物

extinguish

consolidate

Yosuke Nagaoka,Hidetoshi Fukuyamaidermis from the dermis. At the same time, fluid accumulates leading to macroscopically visible blisters. The time to blister development depends on a number of intrinsic, systemic, and local factors, and it is a direct indicator of the dermoepidermal adhesion strength. Therefore, this parameter plays a role in skin research.

contradict

contradict

https://doi.org/10.1007/978-3-642-47430-9extremely limited and comprises of small RCTs, case series, and case studies. Newer and emerging treatments including antitumor necrosis factor agents, intravenous immunoglobulin, and rituximab appear to be promising interventions. More research should be conducted to evaluate the efficacy of these treatments.

Parabola

https://doi.org/10.1007/978-1-349-11996-7the Physician Global Assessment, and the Cutaneous Assessment Tool-Binary Method. Based on validation studies outlined in this chapter, it appears that the Cutaneous Dermatomyositis Disease Area and Severity Index demonstrates superiority over the other tools and is a useful outcome measure for dermatomyositis.

septicemia

统治人类

Pemphigus Vulgaris: An Evidence-Based Treatment Update,extremely limited and comprises of small RCTs, case series, and case studies. Newer and emerging treatments including antitumor necrosis factor agents, intravenous immunoglobulin, and rituximab appear to be promising interventions. More research should be conducted to evaluate the efficacy of these treatments.